Gut Health Campaign
The gut plays an important role in the health and well-being of infants. Early life gut development and maturation is needed to ensure a first line of defence against threats from the external environment¹, microbiota development², proper digestion and absorption of nutrients³, and development of the immune system⁴.
Gut health feeds into many different aspects of health in early life and finds its basis in the colonisation of the gut with beneficial micro-organisms, i.e. the establishment of the infant’s gut microbiota².
A ‘microbiota’ is defined as a collection of micro-organisms residing within a specific part of the body, for instance the gut. Together, all micro-organisms and their activities in various parts of the human body are termed the ‘microbiome’. The development of the gut microbiota in early life has been associated with long-term health effects⁵, highlighting the importance of offering nutritional solutions that can support gut health in infants.
In breast-fed infants, human milk oligosaccharides (HMOs) steer the development of the gut microbiota⁶. HMOs are non-digestible carbohydrates that are fermented by specific bacteria in the infant gut, thereby providing optimal conditions for the growth of beneficial bacteria that support gut health6. So far, over 200 HMO varieties have been identified in human milk6, including 2’-Fucosyllactose (2’-FL), 3’-Sialyllactose (3’-SL) and Lacto-N-Tetraose (LNT), each of which is expected to have its own potential benefits for infant gut health⁷⁻¹². Alongside HMOs, galacto-oligosaccharides (GOS), a complex mixture of over 100 oligosaccharides¹³ that is derived from an enzymatic conversion of lactose from cow’s milk, consists of similar building blocks as HMOs and is recognised for its positive impact on the gut microbiota¹⁴.
At FrieslandCampina Ingredients, we believe that delivering a larger variety of non-digestible oligosaccharides, e.g. a combination of GOS and HMOs, can be of key importance for the establishment of the gut microbiota and its metabolism, thereby feeding into many different health aspects in early life and beyond. As a unique provider of both GOS and HMO solutions, we can offer a wider diversity of structures to bring the concept of gut health to the next level.
‘One gut, a lifetime of opportunity’
For more information: [download material Gut health white paper (short version, 2-pager)]
Benefit areas linked to gut health
Benefit areas linked to gut health
Creating the right environment for beneficial bacteria to grow in the infant gut has been shown to support gut health and other aspects of health and well-being, both in early life as well as later in life²⁺⁵. Four key benefit areas have been identified where the gut microbiota plays an important role in supporting health:
‘One gut, a lifetime of immune health benefits’
In early life, the infant’s immune system has not fully developed and matured yet. Protective immunoglobulins received from the mother during the final stage of pregnancy, as well as protective components in human milk, are important to safeguard the infant’s health. A healthy gut microbiota is of key importance during immune development, since ~70% of the immune system is active in the gut¹⁵. HMOs have been shown to support the development of the immune system via the growth of beneficial bacteria¹⁶. Furthermore, immune development in early life can be supported by strengthening the gut barrier, inhibiting pathogen binding, and modulating the immune response¹⁶.
GOS and HMOs (2’-FL, LNT, 3-Fucosyllactose [3-FL]) serve as substrates for the growth of bifidobacteria⁷⁻¹⁰, leading to the production of metabolites such as short-chain fatty acids (SCFAs)¹⁷. SCFAs can lower the gut pH¹⁴, which further enables the growth of beneficial bacteria¹⁴, and interact with cells of the immune system¹⁷. Furthermore, the growth of beneficial bacteria can crowd out potentially pathogenic bacteria through a competitive advantage¹⁴⁺¹⁸⁺¹⁹.
Specific health outcomes in clinical trials where a reduced incidence of infections was observed have been connected to the presence of GOS in infant formula²⁰⁺²¹. In a study using a formula supplemented with 2’-FL + Lacto-N-neoTetraose (LNnT), the supplemented HMOs increased the number of infants with a gut microbiota composition high in Bifidobacteriaceae. These high Bifidobacteriaceae levels were associated with a decreased risk of requiring antibiotics¹⁹.
Our next HMO on offer, after 2’-FL, will be LNT. LNT is a highly abundant²² neutral core HMO in human milk and has been recognised for its bifidogenic10 and anti-pathogenic activity in vitro¹¹⁺¹².
For more information: [download immune health 2-pager]
‘One gut, a lifetime of digestive health’
In early life, the gastrointestinal tract of infants has not reached a matured stage yet. The digestion and absorption of food can be suboptimal, leading to complaints of gut discomfort in otherwise healthy infants²³. According to FrieslandCampina Ingredients’ and Innova Market Insights’ recent consumer research, the most frequent symptoms reported by parents of infants (0–1 years) are related to gut discomfort²⁴. Moreover, stool consistency and frequency can be altered in formula-fed infants as compared to breast-fed infants²⁵. Overall, gut discomfort often leads to crying and fussing behaviour among infants, which puts pressure on parents and caretakers²³. Solutions to support gut comfort through functional ingredients in infant formula are therefore of key interest.
Increased digestive comfort has been observed in formula-fed infants who received a GOS supplemented formula (4g/L). This improved stool consistency and transit time²⁶⁺²⁷. The underlying mechanisms of action are considered to involve the infant’s gut microbiota, which is positively influenced by GOS¹⁴⁺²⁶.
At FrieslandCampina, we aim to improve and validate our research methods continuously. This has led to a partnership with Wageningen University & Research, Emma’s Children’s Hospital and Sensus to validate the modified Bristol Stool Form Scale (mBSFS) for use in young children. The modified scale can be used by Dutch-speaking parents and caretakers of both toilet-trained and non-toilet-trained toddlers to assess stool consistency and monitor digestive comfort and health²⁸.
For more information: [download digestive health 2-pager]
‘One gut, a lifetime of cognitive health support’
The first year of life is a time of momentous development for the human brain²⁹. Babies start to explore their world and are initiating social interactions. According to new consumer research, more than 50% of parents are concerned about their infant’s cognitive development²⁴. As we learn more and more about the connection between the gut and the brain – the so-called gut-brain axis³⁰, we believe that nutrition is of key importance at this vulnerable stage in life.
Fermentation of non-digestible oligosaccharides by the gut microbiota leads to the release of metabolites like SCFAs and neurotransmitters³¹. By using specific gut-brain pathways, these components can have a direct or indirect influence on neuro-cognitive development and brain function³⁰⁺³².
HMOs are non-digestible carbohydrates that are recognised for their support of the growth of beneficial bacteria in the infant gut¹⁶. Among the HMOs identified to date, 2’-FL is the most abundant type in human milk⁷. 2’-FL has been associated positively with cognitive outcomes and motor skill scores in 18-month-old children³³. In addition, 3’-SL and 6’-SL belong to the acidic type of oligosaccharides named sialyllactoses. These contain sialic acid that is involved in brain development in early life³⁴. 3’-SL has been associated positively with language development in infants³⁵, whereas 6’-SL has been associated positively with cognitive and motor skill scores in 18-month-old children³³. Next to the potential effects of oligosaccharides on infant neurodevelopment, studies also suggest that oligosaccharides can impact mood and well-being: a recent study on GOS supplementation showed a reduction in symptoms of stress and anxiety in a highly anxious group of young adults³⁶.
Bringing these scientific insights together, FrieslandCampina Ingredients is developing a new GOS solution, Vivinal® GOS-SL, that contains sialyllactose structures. This solution may allow us to tap into the cognitive benefits of oligosaccharide supplementation during early life development.
For more information: [download brain health 2-pager]
Growth and Development
‘One gut, a lifetime of healthy growth’
Early life nutrition is of key importance during periods of rapid growth and development. Next to the building blocks and energy derived from macronutrients, micronutrients are essential for the normal development of e.g. bones and tissues. Specifically, calcium and phosphorus are needed in sufficient quantities to ensure bone development in early life, whereas iron and zinc contribute to normal cognitive function³⁷⁻³⁹. Micronutrient deficiencies are not always visible, but can have a lifelong impact on health.
Calcium and iron deficiencies are among the most prevalent in children⁴⁰. The risk of a deficiency can be partially mitigated by a healthy diet that includes food groups that are naturally high in – or fortified with – these micronutrients. However, micronutrients used to fortify foods can have limited bioavailability. The absorption of iron supplements, for instance, is generally poor⁴¹. GOS has been shown to enhance the solubility of minerals in the gut, thereby enhancing their absorption. It has been postulated that the responsible mechanism of action is the reduction of the gut pH by microbiota fermentation of GOS resulting in SCFA formation⁴². GOS has been shown to enhance the absorption of calcium (5g of GOS/day) in young girls⁴³ and iron (7.5g of GOS/day) in infants⁴⁴. In the latter study, GOS simultaneously mitigated the adverse effects of iron supplements on gut microbiota composition disturbance and infection risk⁴⁵. So far, GOS is the only oligosaccharide ingredient that has been shown to have clinically proven effects on iron absorption in children⁴⁴.
Our newly developed ingredient Vivinal® GOS Nutri can support mineral absorption in young children⁴³⁺⁴⁴. The unique light process that we use preserves the naturally occurring minerals and makes Vivinal® GOS Nutri an ingredient that is both suitable and affordable for Young Child Formula (YCF) applications.
For more information: [download growth 2-pager]
Insights from Parents and Health Care Professionals
Today’s parents are health-conscious and highly informed. Together with Innova Market Insights, FrieslandCampina Ingredients conducted a consumer insights survey among parents from seven countries: USA, Brazil, UK, France, Germany, China and Indonesia (n=750 per country)²⁴. At FrieslandCampina Ingredients, we leverage a combination of deep consumer understanding and industry insight to create high-quality ingredient solutions for infant formula manufacturers.
The research revealed that 55% of parents worldwide are concerned about their child’s gut health, with the highest percentage observed among Chinese parents (85%). Parents mostly associate ‘gut health’ with digestive health, while >40% also associate it with immunity, growth and development as well as cognitive function.
For many parents, health care professionals (HCPs) are the key source of advice where optimal nutrition for their infant is concerned. Together with partners Presans and Einerhand Science & Innovation, FrieslandCampina Ingredients conducted an insights survey among paediatricians, neonatologists and dietitians in the UK, USA and China to investigate the future direction of infant nutrition according to HCPs⁴⁶.
Overall, the majority of paediatricians and neonatologists (65%) are conscious about the importance of the gut microbiota in supporting children’s health. HCPs acknowledged DHA, GOS, lactoferrin, 2’-FL and ARA as the most important functional ingredients for infant formula, amongst which GOS and 2’-FL are most strongly associated with gut microbiota and gut health.
For more information: [download HCP and parents survey 2-pagers]
Why FrieslandCampina Ingredients?
Why FrieslandCampina Ingredients?
At FrieslandCampina Ingredients, it is our mission to create and deliver ingredient solutions that are trusted globally to nourish infants to the best extent when breastfeeding is not an option. We believe that a large variety of oligosaccharide structures can offer a wide range of benefits centred around gut health, since each oligosaccharide is expected to have specific modes of action.
FrieslandCampina Ingredients is unique in offering both GOS and HMO¹∙ solutions, thereby providing the opportunity to increase and diversify the total oligosaccharide composition of infant milk formulas. More than 200 HMO structures have been identified in human milk⁶, inspiring infant milk formula manufacturers to expand their oligosaccharide offerings. GOS is a complex mixture of over 100 oligosaccharides derived from the enzymatic conversion of lactose¹³. Moreover, GOS is built up from glucose and galactose, which are also building blocks of HMOs. Adding GOS and HMOs creates a more structurally complete formula suggested to target a wider range of health benefits starting in the gut.
As a result, we are expanding our portfolio with the next generation of HMOs: with 2’-FL already on offer, we are adding LNT and 3’-SL. Our ambition to evolve our prebiotic²∙∙ solutions continuously has also prompted us to develop the next generation of GOS, with a specific focus on SL structures.
Our offerings are supported by high-quality research and designed to enrich a broad range of formula propositions, from affordable to ultra-premium solutions. Backed up by over 75 years of experience in production and research in early life nutrition, we are a proud global leader in the infant milk formula ingredients industry.
Get in touch today. For more information: X
Ingredients on offer
Oligosaccharides are a vitally important component of human milk, not present in cow’s milk. In order to reach the desired levels of oligosaccharides in infant formula, FrieslandCampina Ingredients developed Vivinal® GOS.
Vivinal® GOS Syrup Nutri is a galacto-oligosaccharide ingredient that naturally contains calcium and magnesium.
Aequival® 2’-FL is structurally identical to the oligosaccharide 2’-FL that is found in human milk. The product is a non-GMO ingredient produced with fermentation technology using lactose as a substrate.
Lacto-N-tetraose (LNT) is the most abundant neutral non-fucosylated human milk oligosaccharide (HMO). Findings from preclinical science suggest that LNT can contribute to enhancing Bifidobacteria in the gut and reducing infections with specific pathogens.
Disclaimer: Breastfeeding is the best nutrition for the healthy growth and development of babies. This information is intended for B2B professionals only. Potential consumer benefits are not to be considered as health claims. They should be considered as potential leads that might be developed into health claims that comply with the local legal requirements.
¹∙ Human milk oligosaccharides, not from human milk.
²∙∙ The scientific definition of a prebiotic is ‘a substrate that is selectively utilised by host microorganisms conferring a health benefit’. Gibson GR, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. Whether the claim ‘prebiotic’ can be used on consumer products depends on local legislation.
- Field, C. J. Recent Advances in Nutritional Sciences The Immunological Components of Human Milk and Their Effect on Immune Development in Infants 1 , 2. 1–4 (2005).
- Turfkruyer, M. & Verhasselt, V. Breast milk and its impact on maturation of the neonatal immune system. Curr Opin Infect Dis 28, 199–206 (2015).
- Vighi, G., Marcucci, F., Sensi, L., Di Cara, G. & Frati, F. Allergy and the gastrointestinal system. Clin. Exp. Immunol. 153, 3–6 (2008)
- Ximenez, C. & Torres, J. Development of Microbiota in Infants and its Role in Maturation of Gut Mucosa and Immune System. Arch. Med. Res. 48, 666–680 (2017)
- Anderson RC, MacGibbon AKH, Haggarty N, et al (2018) Bovine dairy complex lipids improve in vitro measures of small intestinal epithelial barrier integrity. PLoS One. 2018 Jan 5;13(1):e0190839.
- Motouri M, Matsuyama H, Yamamura J, et al (2003) Milk sphingomyelin accelerates enzymatic and morphological maturation of the intestine in artificially reared rats. J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):241-7
- Lee H, Zavaleta N, Chen S-Y, et al (2018) Effect of bovine milk fat globule membranes as a complementary food on the serum metabolome and immune markers of 6-11-month-old Peruvian infants. npj Sci Food 2:6.
- Snow DR, Ward RE, Olsen a, et al (2011) Membrane-rich milk fat diet provides protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. J Dairy Sci 94:2201–2212.
- Bhinder G, Allaire JM, Garcia C, et al (2017) Milk Fat Globule Membrane Supplementation in Formula Modulates the Neonatal Gut Microbiome and Normalizes Intestinal Development. Sci Rep 7:45274.
- Zavaleta, N. et al. Efficacy of an MFGM-enriched complementary food in diarrhea, anemia, and micronutrient status in infants. J. Pediatr. Gastroenterol. Nutr. 53, 561–568 (2011).
- Timby, N. et al. Infections in infants fed formula supplemented with bovine milk fat globule membranes. J. Pediatr. Gastroenterol. Nutr. 60, 384–389 (2015).
- Li F, Wu SS, Berseth CL, et al (2019) Improved Neurodevelopmental Outcomes Associated with Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula: A Randomized, Controlled Trial. J Pediatr 215:24-31.e8.
- Veereman-Wauters, G. et al. Milk fat globule membrane (INPULSE) enriched formula milk decreases febrile episodes and may improve behavioral regulation in young children. Nutrition 28, 749–752 (2012).
- Donovan, Sharon M. 2016. “The Role of Lactoferrin in Gastrointestinal and Immune Development and Function: A Preclinical Perspective.” Journal of Pediatrics 173. Elsevier Inc.: S16–28. doi:10.1016/j.jpeds.2016.02.072.
- Manzoni, P. Clinical Benefits of Lactoferrin for Infants and Children. J. Pediatr. 173, S43–S52 (2016).
- Chen, K. et al. Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial. Nutrition 32, 222–227 (2016[DD(1] )
- King, J. C. et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J. Pediatr. Gastroenterol. Nutr. 44, 245–251 (2007).
- Gao, Y. et al. Enteral Lactoferrin Supplementation for Preventing Sepsis and Necrotizing Enterocolitis in Preterm Infants : A Meta‑Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Front. Pharmacol. 11, 1186 (2020).
- Tarnow-Mordi, William O., Mohamed E. Abdel-Latif, Andrew Martin, Mohan Pammi, Kristy Robledo, Paolo Manzoni, David Osborn, et al. 2020. “The Effect of Lactoferrin Supplementation on Death or Major Morbidity in Very Low Birthweight Infants (LIFT): A Multicentre, Double-Blind, Randomised Controlled Trial.” The Lancet Child and Adolescent Health 4 (6): 444–54.
- Johnston, W. H. et al. Growth and tolerance of formula with lactoferrin in infants through one year of age: double-blind, randomized, controlled trial. BMC Pediatr. 15, 173 (2015).
- Ben, X.-M. et al. Supplementation of milk formula with galacto-oligosaccharides improves intestinal micro-flora and fermentation in infants. Chin. Med. J. (Engl). 117, 927–931 (2004).
- Fanaro, S. et al. Galacto-oligosaccharides are bifidogenic and safe at weaning: a double-blind randomized multicenter study. J. Pediatr. Gastroenterol. Nutr. 48, 82–8 (2009).
- Arslanoglu, S., Moro, G. E. & Boehm, G. Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. J. Nutr. 137, 2420–4 (2007).
- Arslanoglu, S. et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J. Nutr. 138, 1091–1095 (2008).
- Ranucci, G. et al. Galacto-oligosaccharide/polidextrose enriched formula protects against respiratory infections in infants at high risk of atopy: A randomized clinical trial. Nutrients 10, (2018).
- Akbari, P. et al. Galacto-oligosaccharides Protect the Intestinal Barrier by Maintaining the Tight Junction Network and Modulating the Inflammatory Responses after a Challenge with the Mycotoxin Deoxynivalenol in Human Caco-2 Cell. J Nutr 145, 1604–1613 (2015).
- Krumbeck, J. A., Rasmussen, H. E., Hutkins, R. W., Clarke, J. & Shawron, K. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome 6, 1–16 (2018).
- Yu, Z. T. et al. The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology 23, 169–177 (2013).
- Lewis, Z. T. et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 3, 13 (2015).
- Weichert, S. et al. Bioengineered 2’-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutr. Res. 33, 831–8 (2013).
- Morrow, A. L. et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J. Pediatr. 145, 297–303 (2004).
- Puccio, G. et al. Effects of Infant Formula with Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial. JPGN 64, 624–631 (2017).
- Reverri, E., Devitt, A., Kajzer, J., Baggs, G. & Borschel, M. Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose. Nutrients 10, 1346 (2018).
- Holscher, H. D., Davis, S. R. & Tappenden, K. A. Human milk oligosaccharides influence maturation of human intestinal Caco-2Bbe and HT-29 cell lines. J. Nutr. 144, 586–91 (2014).
- Autran, C. A., Schoterman, M. H. C., Jantscher-Krenn, E., Kamerling, J. P. & Bode, L. Sialylated galacto-oligosaccharides and 2’-fucosyllactose reduce necrotising enterocolitis in neonatal rats. Br. J. Nutr. 116, 294–299 (2016).
- Goehring, K. C. et al. Similar to Those Who Are Breastfed , Infants Fed a Formula Containing 2’-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized. J Nutr 146, 2559–2566 (2016).
- Field CJ, Van Aerde JE, Robinson LE, Clandinin MT. (2008) Effect of providing a formula supplemented with long-chain polyunsaturated fatty acids on immunity in full-term neonates. Br J Nutr. 2008 Jan;99(1):91-9.
- Lapillone A. Enteral and Parenteral Lipid Requirements of Preterm Infants. In: Koletzko B, Poindexter B, Uauy R, editors. Nutr. Care Preterm Infants Sci. Basis Pract. Guidel., Basel: Karger; 2014, p. 82–98. doi:10.1159/000358460.
- Birch EE, Khoury JC, Berseth CL, Castañeda YS, Couch JM, Bean J, et al. The Impact of Early Nutrition on Incidence of Allergic Manifestations and Common Respiratory Illnesses in Children. J Pediatr 2010;156:902-906.e1. doi:10.1016/j.jpeds.2010.01.002.
- Field CJ, Van Aerde JE, Robinson LE, Thomas Clandinin M. Effect of providing a formula supplemented with long-chain polyunsaturated fatty acids on immunity in full-term neonates. Br J Nutr 2008;99:91–9. doi:10.1017/S0007114507791845.
- Radzikowska U, Rinaldi AO, Çelebi Sözener Z, et al (2019) The Influence of Dietary Fatty Acids on Immune Responses. Nutrients. 2019 Dec 6;11(12):2990.
- Bermudez-Brito, M. et al. The impact of dietary fibers on dendritic cell responses in vitro is dependent on the differential effects of the fibers on intestinal epithelial cells. Mol Nutr Food Res 59, 698–710 (2015).
- Schouten, B. et al. A Potential Role for CD25+ Regulatory T-cells in the Protection Against Casein Allergy by Dietary Non-Digestible Carbohydrates. J. Nutr. 107, 96–105 (2012).
- Jeurink, P. V, van Esch, B. C. A. M., Rijnierse, A., Garssen, J. & Knippels, L. M. J. Mechanisms underlying immune effects of dietary oligosaccharides. J. Clin. Nutr. 98, 572S–577S (2013).
- Drago-Serrano, M., Campos-Rodríguez, R., Carrero, J. & de la Garza, M. Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections. Int. J. Mol. Sci. 18, 501 (2017).
- Kruzel, M. L., Zimecki, M. & Actor, J. K. Lactoferrin in a context of inflammation-induced pathology. Frontiers in Immunology 8, (2017).